1 4 9 1 l e t t e r S Human cancer genome sequencing has recently revealed that genes that encode subunits of SWI/SNF chromatin remodeling complexes are frequently mutated across a wide variety of cancers, and several subunits of the complex have been shown to have bona fide tumor suppressor activity 1 . However, whether mutations in SWI/SNF subunits result in shared dependencies is unknown. Here we show that EZH2, a catalytic subunit of the polycomb repressive complex 2 (PRC2), is essential in all tested cancer cell lines and xenografts harboring mutations of the SWI/SNF subunits ARID1A, PBRM1, and SMARCA4, which are several of the most frequently mutated SWI/SNF subunits in human cancer, but that co-occurrence of a Ras pathway mutation is correlated with abrogation of this dependence. Notably, we demonstrate that SWI/SNF-mutant cancer cells are primarily dependent on a non-catalytic role of EZH2 in the stabilization of the PRC2 complex, and that they are only partially dependent on EZH2 histone methyltransferase activity. These results not only reveal a shared dependency of cancers with genetic alterations in SWI/SNF subunits, but also suggest that EZH2 enzymatic inhibitors now in clinical development may not fully suppress the oncogenic activity of EZH2. SWI/SNF (or BRG1-associated factors (BAF)) complexes contribute to transcriptional regulation and DNA repair by hydrolyzing ATP to remodel chromatin structure. The complexes consist of combinatorial assemblies of approximately 15 subunits, including lineage-restricted variant subunits, resulting in a diversity of SWI/SNF complexes that contribute to the control of lineage-specific gene expression 2 . Cancer genome sequencing studies revealed that at least nine SWI/SNF subunits are recurrently mutated in 20% of all cancers, and mouse studies have shown that SWI/SNF subunits are bona fide tumor suppressors 1,3-18 . Although recurrent mutation of nine subunits suggests a shared oncogenic mechanism, the tumor spectra associated with each subunit are distinct, and diverse phenotypic consequences arise from ablation of SWI/SNF subunit genes in mice.
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Genetic studies in Drosophila first identified antagonistic links between polycomb group (PcG) genes and the SWI/SNF complex 19 , revealing that mutations in the Swi/Snf complex are capable of suppressing phenotypes associated with PcG gene mutations, and that PcG proteins can block SWI/SNF-mediated nucleosome mobilization [20] [21] [22] . The PRC2 complex consists of four core subunits: EZH2, the catalytic subunit that methylates H3K27 to repress transcription, as well as SUZ12, EED, and RaAp46/48 (refs. 23-25) . High levels of EZH2 often correlate with tumor stage and poor prognosis, and deletion of EZH2 can block proliferation and survival in cell lines and mouse models. Consequently, EZH2 is a potential therapeutic target and several inhibitors are in development, including clinical trials [26] [27] [28] [29] . Efforts to therapeutically target EZH2 have generally focused upon inhibition of its histone methyltransferase activity, although it remains unclear whether this is the central mechanism by which EZH2 can promote cancer.
In mammals, we and others have demonstrated an antagonistic relationship between EZH2 and the SMARCB1 (also known as SNF5, INI1 and BAF47) subunit of the SWI/SNF complex, which results in genetic dependence on EZH2 in SMARCB1-mutated cancers [30] [31] [32] . However, whether a similar relationship broadly exists between EZH2 and mutated SWI/SNF subunits is unclear. To evaluate this, we used human cancer cell lines mutant for the ARID1A, SMARCA4 (also known as BRG1), PBRM1, or SMARCB1 (also known as SNF5) subunits of SWI/SNF 1,13,33 and four control lines (ES2, SKM-1, Toledo, and OCI-LY-19) that express both wild-type SWI/SNF-complex members and EZH2/PRC2-complex members ( Supplementary  Fig. 1a) . Knockdown of EZH2 reduced H3K27 di-and trimethylation (Supplementary Fig. 1b) . Depletion of EZH2 did not affect control cell lines (Fig. 1a and Supplementary Fig. 1c ), but it did impair proliferation and colony formation of SWI/SNF-mutant cancer cell lines (Fig. 1a,b and Supplementary Fig. 1d,e) . Re-expression l e t t e r S 1 4 9 2 VOLUME 21 | NUMBER 12 | DECEMBER 2015 nature medicine of wild-type EZH2 using a construct not recognized by the shRNAs rescued H3K27 trimethylation, cell proliferation, and colony formation in a dose-dependent manner (Supplementary Fig. 2 ). To further examine the dependency of SWI/SNF-mutant cancers on EZH2, we used isogenic knockout of ARID1A in HCT116 cells (wildtype, heterozygous deficient for ARID1A, or homozygous deficient for ARID1A) (Fig. 1c) . EZH2 knockdown impaired proliferation and colony formation only in cell lines with homozygous ARID1A inactivation ( Fig. 1d and Supplementary Fig. 2b ). using hundreds of cancer cell lines [34] [35] [36] [37] . We first evaluated whether cell lines that contained EZH2 gain-of-function activating mutations were sensitive to PRC2 subunit (EZH2, SUZ12, or EED) loss. Although there were only three such lines, all scored as dependent on each PRC2 subunit ( Supplementary Fig. 3a-c) . When compared to SWI/SNF wild-type lines, lines that contained biallelic inactivating mutations of a SWI/SNF subunit (herein termed SWI/SNF mutant) were also dependent on EZH2 expression (P = 0.0087), EED (P = 0.0023), and SUZ12 (P = 0.0314) (Supplementary Fig. 3d-f 
npg l e t t e r S mutations 38 , we asked whether activating Ras pathway mutations (in KRAS, HRAS, NRAS, or BRAF) accounted for SWI/SNF-mutant cell lines that did not display PRC2 dependence. Lines with wild-type
Ras pathways were, in fact, more dependent on EZH2 (P = 0.0009), EED (P = 0.0039), and SUZ12 (P < 0.0001) than lines with activating Ras pathway mutations ( Supplementary Fig. 3g−i) . When we removed lines with Ras mutations from our analysis, SWI/SNF-mutant lines displayed a greater dependence on EZH2 (P < 0.0001), EED (P = 0.0005), and SUZ12 (P < 0.0001) ( Fig. 1e and Supplementary  Fig. 3j,k) . Strikingly, almost all of the SWI/SNF-mutant cell lines that did not show PRC2 dependence in the initial analysis contained activating Ras pathway mutations (compare Supplementary Fig. 3d-f to Fig. 1e and Supplementary Fig. 3j,k) . Taken together, these data indicate that SWI/SNF-mutant cell lines are dependent on the presence of PRC2, but that the presence of Ras mutations can abrogate this dependence. This suggests that Ras-pathway mutation may reduce dependence on EZH2 and even perhaps that EZH2 inhibition might enhance proliferation in the setting of Ras mutation. We next investigated the effect of a small-molecule inhibitor of EZH2 on SWI/SNF-mutant cancer cell proliferation. GSK126 is an S-adenosyl-methionine-competitive binder of EZH2 that inhibits its histone methyltransferase activity and induces a loss of H3K27 trimethylation without affecting levels of total histone H3 or other PRC2 components 27 . Positive-control SMARCB-mutated rhabdoid tumor cell lines were most sensitive to GSK126 (Supplementary Fig. 4) , consistent with our prior identification of EZH2 dependence in these cancers. Six of ten cancer cell lines containing SWI/SNF subunit mutations also showed sensitivity beginning at a GSK126 dose of 2.5 µM (Fig. 2a and Supplementary Fig. 4b ). To more directly evaluate the effects of SWI/SNF-subunit mutation, we generated mouse embryonic fibroblasts (MEFs) conditional for Arid1a (encoding AT-rich interactive domain 1A (SWI-like)). GSK126 efficiently reduced the levels of H3K27 trimethylation in both cases, but Arid1a-depleted MEFs showed higher sensitivity to EZH2 inhibition than the wild-type MEFs (Supplementary Fig. 4c-e) . We next examined the several SWI/SNFmutant lines that did not respond until a tenfold increase in GSK126 concentration, up to 20 µM (Fig. 2a,b) . Regardless of whether the cells were sensitive or resistant to GSK126, even the lowest dose of 2 µM of GSK126 caused marked reduction in H3K27 trimethylation levels (Fig. 2b) . We also tested these cells with additional enzymatic inhibitors (EZ005, GSK343) with similar results (Supplementary Fig. 4f,g ).
Given that all SWI/SNF-mutant lines were sensitive to knockdown of EZH2 but displayed discrepant responses to the EZH2 enzymatic inhibitor, we sought to further characterize the mechanistic and functional requirements for EZH2. Expression of EZH2-∆SET, in which the methyltransferase domain has been deleted, conferred substantial rescue activity (Fig. 2c) , suggesting that loss of the enzymatic function of EZH2 only partially accounted for the effects of EZH2 knockdown. We also tested the effect of a catalytically inactive point-mutant EZH2 (F672I/H694A/R732K). Unlike wild-type EZH2, catalytically inactive mutant EZH2 did not rescue the levels of H3K27 trimethylation (Fig. 2d,f and Supplementary Fig. 4h,j) , but it did rescue the effect of EZH2 knockdown in the GSK126-resistant cell lines (Fig. 2d-g and Supplementary Fig. 4h-n) .
To further investigate the response discrepancies between shRNAmediated knockdown and response to enzymatic inhibitors, we used the recently described stabilized α-helix of EZH2 (SAH-EZH2) stapled peptides to block H3K27 trimethylation in a dose-dependent manner by disrupting formation of the EZH2-EED interaction within PRC2 (ref. 39) . In contrast to the enzymatic inhibitors, inhibition of PRC2 function via stapled peptides results in degradation of EZH2, thus eliminating not only its enzymatic activity but also any structural contribution. We treated our panel of genetically distinct cancer cell lines with two different SAH-EZH2 stapled peptides (Supplementary Table 1 ). Treatment with either SAH-EZH2 stapled peptide resulted in decreased levels of both EZH2 and H3K27 trimethylation and impaired the growth of SWI/SNF-mutant cells, while control peptides had no effect (Fig. 2h,i) . Notably, the RCC4 and H1299 cell lines, which were resistant to the GSK126 enzymatic inhibitor, were sensitive to the SAH-EZH2 peptides (Fig. 2i) . These results suggest that the growth of some SWI/SNF-mutant cancers is dependent on EZH2, but independent of its catalytic activity.
To search for potential mechanisms underlying these differential responses, we first tested the effect of GSK126 on H3K27 trimethylation in both sensitive and resistant cell lines, and we found that it was equally effective (Fig. 3a) . Previous studies have indicated that phosphorylation of EZH2 at Thr487, which is located in the SUZ12 binding domain (Fig. 3a) , destabilizes the PRC2 complex 40 . We therefore evaluated Thr487 phosphorylation in cell lines treated with GSK126. Levels of Thr487 increased in GSK126-sensitive cell lines (G401, HEC59, and, A704, and TOV21G) upon GSK126 treatment ( Fig. 3b and Supplementary Fig. 5a ), but they were substantially decreased in GSK126-resistant cell lines (RCC4, OVISE and, H1299) (Fig. 3a,c) . Correspondingly, in GSK126-sensitive cells, the addition of GSK126 destabilized the SUZ12-EZH2 interaction (Fig. 3d) , but it had the opposite effect in GSK126-resistant cells (Fig. 3e-g ). Other GSK126-sensitive cell lines (HEC59, A704, and TOV21G) also showed increased levels of Thr487 phosphorylation and reduced SUZ12-EZH2 interaction after GSK126 treatment (Supplementary Fig. 5a ). Two additional GSK126-resistant cell lines (H1299 and OVISE) showed substantial reductions in Thr487 phosphorylation and stabilization of SUZ12-EZH2 interactions after GSK126 treatment (Fig. 3c,e-g ). Consistent with the previous report 40 , we found that Thr487-phosphorylated EZH2 did not interact with SUZ12 ( Supplementary  Fig. 5b) . Notably, we found that interaction with EED, which occurs in an amino-terminal domain of EZH2 far from Thr487, was minimally affected by GSK126 treatment (Fig. 4) . SWI/SNF wild-type control lines (OCI-LY-19 and Toledo), which are not dependent on EZH2 in any assay, showed no change in the levels of phosphorylated EZH2 in response to GSK126 (Supplementary Fig. 5c ). Collectively, these results both reveal a shared dependency of SWI/SNF-mutant cancers on PRC2 integrity and further indicate that enzymatic inhibitors of EZH2 may not fully suppress its oncogenic activity unless they are capable of disrupting the protein interactions of the PRC2 complex.
To determine whether the sensitive and resistant response to EZH2-inhibiting compound could be observed in vivo, we injected a GSK126-sensitive SWI/SNF-mutant cell line, A549, and a GSK126-resistant SWI/SNF-mutant cancer cell line, H1299, into the flanks of recipient mice. Once the tumors reached 200 mm 3 in volume we randomly assigned mice into two groups (n = 4 mice per group) and began daily treatment with vehicle control (20% Captisol) or GSK126 (150 mg/kg in Captisol) by intraperitoneal injection for 28 d. Consistent with the effects observed in culture, GSK126 reduced the levels of H3K27me3 and blocked the growth of sensitive A549 tumors (Fig. 4a-c and Supplementary Fig. 5d ), but it had no effect on the growth of the resistant H1299 tumors (Fig. 4d-f and Supplementary Fig. 5e ).
We conclude that the dependence on EZH2 in some SWI/SNFmutant cancers is largely dictated by a non-enzymatic contribution of EZH2, perhaps to stabilization of PRC2, rather than by the enzymatic activity of EZH2 per se. As EZH2 has been shown to have both PRC2-dependent and enzyme-dependent functions in transcriptional repression as well as PRC2-independent and enzymaticindependent contributions to the recruitment of co-regulators and to transcriptional regulation 41 , our findings suggest that mutation of SWI/SNF subunits can create dependence on both functions of EZH2. Collectively, these results reveal a shared dependency of SWI/SNFmutant cancers on EZH2 function and further indicate that enzymatic inhibitors of EZH2 may not fully suppress its oncogenic activity unless they are capable of disrupting the protein interactions of the PRC2 complex. Thus, these findings inform the mechanistic requirements of the next generation of EZH2 inhibitors for optimal blockade of pathologic PRC2 activity.
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